Back to results
US 2022/0016171 A1Published application
Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite De Paris, Assistance Publique-HôPitaux De Paris (Aphp), Institut Curie
InventorsOlivier LANTZ, Sophie CAILLAT-ZUCMAN
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to immunotherapy, in particular immunotherapy for treating cancer, infectious diseases or autoimmune diseases. More specifically, the invention relates to Mucosal-Associated Invariant T (MAIT) cells expressing Chimeric Antigen Receptors (CARs), wherein the MAIT cell is allogenic with respect to the subject to be treated.
Claims15
A method of treating a cancer, an immune disease or an infectious disease in a subject in need thereof, comprising
- administering to the subject a therapeutically effective amount of mucosa associated invariant T (MAIT) cells expressing a chimeric antigen receptor (CAR),
- wherein the MAIT cells are allogenic with respect to the subject.
Dependencies are inferred from the claim text.